Tauroursodeoxycholic Acid Induces Liver Regeneration and Alleviates Fibrosis Through GATA3 Activation.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and rodent research
PubMed 40299532 · doi:10.3390/biomedicines13040910
What was done
The researchers examined the effects of tauroursodeoxycholic acid (TUDCA) on hepatocyte proliferation and hepatic fibrosis. Investigations used BRL-3A rat liver cells (including GATA3-knockdown cells) alongside two in vivo rat models: a partial hepatectomy liver regeneration model and a carbon tetrachloride (CCl4)-induced liver fibrosis model.
What was found
The abstract reports purely directional findings without quantitative figures or statistical values. TUDCA increased the proliferation of BRL-3A cells, enhanced liver regeneration following partial hepatectomy in rats, and reduced liver fibrosis in CCl4-treated rats. The proliferative effect of TUDCA on BRL-3A cells was abolished when GATA3 was knocked down.
Why it matters
These findings suggest TUDCA may help support liver regeneration and attenuate fibrosis through a GATA3-mediated mechanism, offering a potential therapeutic avenue for liver injury and post-surgical recovery.
Limits
The study is entirely preclinical, relying on rodent models and a cell line with no human clinical data. The abstract does not disclose sample sizes (n), drug dosages, treatment durations, or specific numerical effect sizes and confidence intervals.
Cited by
- supports TUDCA thins biliary sludge in the bile ducts and reduces liver fibrosis.